

### MANUFACTURING/IMPORT AUTHORISATION

- 1. Authorisation number/reference number
- Name of the holder of the 2. authorisation
- 3. Address(es) of the manufacturer's / importer's place(s) of operation
- Registered address of the holder of 4. the authorisation
- 5. Scope of the authorisation and dosage forms
- Legal basis on which authorisation was 6. granted

- Name of the responsible officer of the responsible authority of the Member State granting the authorisation
- 8.
- 9.
- 10. Annexes

DE BY 04 MIA 2025 0081/ROB-53Ph-2677.Ph 2-467

PharmaKorell GmbH

(LOC-100076822) PharmaKorell GmbH

Schleißheimer Straße 373

80935 München

(LOC-100076822)

Schleißheimer Straße 373

80935 München

ANNEX 1 and 2

Section 13 para. 1 of the German Pharmaceuticals Act (AMG)

Section 72 para. 1 of the German Pharmaceuticals Act (AMG)

Article 61 paragraphs 1 to 3 of Regulation EU No. 536/2014 in connection with Section 13 para. 5 of the German Pharmaceuticals Act (AMG)

Article 61 paragraphs 1 to 3 of Regulation EU No. 536/2014 in connection with Section 72 para. 2a of

the German Pharmaceuticals Act (AMG)

Signature

Date

[Signature: illegible] 22 Oct. 2025

Annex 1 and Annex 2

Annex 4 (address(es) of test centres commissioned)

Annex 5 (names of the expert persons)

Annex 8 (list of products covered by the

DE BY 04 MIA 2025 0081 [Raised Seal: illegible] Page 1 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025



Dierk Bode

manufacturing/import authorisation)

[Raised Seal: illegible]

DE\_BY\_04\_MIA\_2025\_0081

Page 2 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025



Dierk Bode

Annex 1

### SCOPE OF THE AUTHORISATION

Name and address of the place of operation:

PharmaKorell GmbH, Schleißheimer Straße 373, 80935 München/Munich

Pharmaceutical products for human use

## PERMITTED ACTIVITIES

Manufacturing activities (according to part 1)

Import of pharmaceutical products (according to part 2)

Part 1 – MANUFACTURING ACTIVITIES			
1.1	Sterile products		
	1.1.3 Batch certification		
1.2	Non-sterile products		
	1.2.2 Batch certification		
1.3	Biological pharmaceutical products		
	1.3.2 Batch certification		
	1.3.2.5 Biotechnological products		

Restrictions or clarifications regarding the manufacturing activities

Batch certification also includes the certification of intermediate products

[Raised Seal: illegible]

DE\_BY\_04\_MIA\_2025\_0081

Page 3 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025

beeldigter
Urkundenübersetzer

\* sworn-in
document translator

Dierk Bode

# Certified translation from the German language

Part 2 – IMPORT OF PHARMACEUTICAL PRODUCTS					
2.2	Batch certification for imported pharmaceuticals				
	2.2.1	Sterile products			
		2.2.1.1 Aseptically manufactured			
		2.2.1.2 Sterilised in the final container			
	2.2.2	Non-sterile products			
	2.2.3	Biological pharmaceuticals			
		2.2.3.1 Blood products			
		Other preparations originating from foreign blood			
		2.2.3.5 Biotechnological products			

Restrictions or clarifications regarding the import activities

Place of operation for physical import is PharmaKorell GmbH, Georges-Köhler-Str. 2, 79539 Lörrach

[Raised Seal: illegible]

DE\_BY\_04\_MIA\_2025\_0081

Page 4 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025



Dierk Bode

Annex 2

### SCOPE OF THE AUTHORISATION

Name and address of the place of operation:

PharmaKorell GmbH, Schleißheimer Straße 373, 80935 München/Munich

Investigational medicinal products for human use

## PERMITTED ACTIVITIES

Manufacturing activities (according to part 1)

Import of investigational medicinal products (according to part 2)

Part 1 – MANUFACTURING ACTIVITIES			
1.1	Sterile products		
	1.1.3 Batch certification		
1.2	Non-sterile products		
	1.2.2 Batch certification		
1.3	Biological pharmaceutical products		
	1.3.2 Batch certification		
	1.3.2.5 Biotechnological products		

Restrictions or clarifications regarding the manufacturing activities

Batch certification also includes the certification of intermediate products

[Raised Seal: illegible]

DE\_BY\_04\_MIA\_2025\_0081

Page 5 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025

beeidigter
Urkundenübersetzer

\* sworn-in
document translator

Dierk Bode

# Certified translation from the German language

Part 2 – IMPORT OF INVESTIGATIONAL MEDICINAL PRODUCTS					
2.2	Batch certification for imported investigational medicinal products				
	2.2.1	Sterile products			
		2.2.1.1 Aseptically manufactured			
		2.2.1.2 Sterilised in the final container			
	2.2.2	Non-sterile products			
	2.2.3	Biological pharmaceuticals			
		2.2.3.5 Biotechnological products			

Restrictions or clarifications regarding the import activities

Place of operation for physical import is PharmaKorell GmbH, Georges-Köhler-Str. 2, 79539 Lörrach

[Raised Seal: illegible]

DE\_BY\_04\_MIA\_2025\_0081

Page 6 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025



Dierk Bode

Annex 4

Address(es) of test centres commissioned

Untersuchungsinstitut Heppeler Marie-Curie-Strasse 7 79539 Lörrach Chemical/physical /microbiological (non-sterile)

Labor LS SE & Co. KG Mangelsfeld 4, 5, 6 97708 Bad Bocklet-Großenbrach Microbiological (sterile and non-sterile)/ Endotoxin test

[Raised Seal: illegible]

DE\_BY\_04\_MIA\_2025\_0081

Page 7 of 9

22 Oct. 2025 14:27:06

The above translation of a document written in the German language submitted to me in PDF format is correct and complete.

Eimeldingen, 20 November 2025



Dierk Bode